Bayer’s Finerenone CKD Trial Completion: What Investors Should Watch Next
Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bayer’s phase 3 trial “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease” tests whether finerenone can safely slow kidney damage. The study matters because it targets a large patient group with limited non-diabetic CKD options.
The trial tests finerenone tablets versus a placebo, both taken once daily on top of standard care. Finerenone is designed to block aldosterone, a hormone that can drive inflammation and scarring in the kidney and heart.
The study is interventional and randomized, meaning participants are assigned by chance to finerenone or placebo. It uses a double-blind, placebo-controlled, parallel-group design so neither patients nor doctors know who gets the drug, helping reduce bias and keep results reliable.
The trial began after first submission in Sept. 2021 and ran for up to about 50 months per participant, tracking kidney function and safety over time. The status is now listed as completed, and Bayer submitted the most recent update on Feb. 12, 2026, signaling that top-line data may be near or under review.
A positive finerenone readout in non-diabetic CKD would extend Bayer’s cardiorenal franchise beyond current diabetic CKD use, supporting sentiment for BAYRY by opening a broader addressable market. It would also raise competitive pressure for rivals in kidney care and cardiorenal drugs, including SGLT2 players and newer CKD candidates.
Conversely, weak efficacy or safety signals could cap enthusiasm and shift investor focus back to Bayer’s other pipeline and restructuring moves, while benefiting competitors positioned in CKD. With the trial now completed and the record recently updated, the study remains active in follow-up and reporting, and further details are available on the ClinicalTrials.gov portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.
